Condition

Amyotrophic Lateral Sclerosis (ALS)

Compensation

Variable

Duration

Amyotrophic Lateral Sclerosis (ALS)

Official Title

Amyotrophic Lateral Sclerosis (ALS)

Study Summary

This first-in-human, double-blind, placebo-controlled Phase I study will be conducted in participants with amyotrophic lateral sclerosis (ALS) to explore safety, tolerability, and pharmacokinetic (PK) properties of GDC-0134. It will include three components: a Single-Ascending-Dose (SAD) stage, a Multiple-Ascending-Dose (MAD) stage, and an Open-Label Safety Expansion (OSE) stage.

Eligibility and Recruitment Information

Recruitment Status Recruiting
Eligible Genders Both
Eligible Ages 18+
Inclusion ALS Diagnosis
Exclusion ALS Diagnosis
Start Date
Compensation Variable
Location Orlando, FL

Study Information

Condition Amyotrophic Lateral Sclerosis (ALS)
Study Phase Phase 1

Administrative Information

Study ID NEUROLOGICAL
Investigators Ira Goodman, MD

Apply for this study

Please include your first name.
Please include your last name.
Please include a valid email address.
loading
Thank you for applying.
Sorry, something wen't wrong. Please contact us for support.